Grace Therapeutics Statistics Share Statistics Grace Therapeutics has 13.83M
shares outstanding. The number of shares has increased by null%
in one year.
Shares Outstanding 13.83M Shares Change (YoY) n/a Shares Change (QoQ) n/a Owned by Institutions (%) 34.97% Shares Floating n/a Failed to Deliver (FTD) Shares 439 FTD / Avg. Volume 0.71%
Short Selling Information The latest short interest is 76.31K, so 0.55% of the outstanding
shares have been sold short.
Short Interest 76.31K Short % of Shares Out 0.55% Short % of Float 0.66% Short Ratio (days to cover) 1.24
Valuation Ratios The PE ratio is -2.16 and the forward
PE ratio is -3.59.
Grace Therapeutics's PEG ratio is
0.04.
PE Ratio -2.16 Forward PE -3.59 PS Ratio 0 Forward PS 100.5 PB Ratio 0.41 P/FCF Ratio -1.85 PEG Ratio 0.04
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Grace Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 11.77,
with a Debt / Equity ratio of 0.
Current Ratio 11.77 Quick Ratio 11.77 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-3.19M Employee Count 4 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -3.2M Effective Tax Rate 25.06%
Stock Price Statistics The stock price has increased by null% in the
last 52 weeks. The beta is 0.72, so Grace Therapeutics's
price volatility has been higher than the market average.
Beta 0.72 52-Week Price Change n/a 50-Day Moving Average 3.09 200-Day Moving Average 3.08 Relative Strength Index (RSI) 56.13 Average Volume (20 Days) 62,238
Income Statement
Revenue n/a Gross Profit -7K Operating Income -16.68M Net Income -12.77M EBITDA -12.76M EBIT -12.77M Earnings Per Share (EPS) -0.79
Full Income Statement Balance Sheet The company has 22.13M in cash and 0 in
debt, giving a net cash position of 22.13M.
Cash & Cash Equivalents 22.13M Total Debt n/a Net Cash n/a Retained Earnings -220.69M Total Assets 69.81M Working Capital 18.21M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -14.9M
and capital expenditures 0, giving a free cash flow of -14.9M.
Operating Cash Flow -14.9M Capital Expenditures n/a Free Cash Flow -14.9M FCF Per Share -1.23
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields GRCE does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for GRCE is $12,
which is 267% higher than the current price. The consensus rating is "Buy".
Price Target $12 Price Target Difference 267% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jul 10, 2023. It was a
backward
split with a ratio of 1:6.
Last Split Date Jul 10, 2023 Split Type backward Split Ratio 1:6
Scores Altman Z-Score -0.24 Piotroski F-Score 2
